Published in Epilepsia on May 23, 2007
Epilepsy surgery trends in the United States, 1990-2008. Neurology (2012) 2.97
Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology (2012) 2.36
Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med (2008) 1.48
Response to placebo in clinical epilepsy trials-Old ideas and new insights. Epilepsy Res (2016) 0.96
Minimally invasive surgical approaches for temporal lobe epilepsy. Epilepsy Behav (2015) 0.88
Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs (2013) 0.87
Pregabalin for the management of partial epilepsy. Neuropsychiatr Dis Treat (2008) 0.83
Meta-analyses of antiepileptic drugs for refractory partial (focal) epilepsy: an observation. Br J Clin Pharmacol (2013) 0.80
Network meta-analyses of antiepileptic drug efficacy and tolerability in drug-resistant focal epilepsies: a clinical perspective. Eur J Clin Pharmacol (2014) 0.79
Tiagabine: efficacy and safety in partial seizures - current status. Neuropsychiatr Dis Treat (2008) 0.79
Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial. Acta Neurol Scand (2013) 0.79
Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat (2013) 0.79
Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurol (2010) 0.78
Seizure outcomes in nonresective epilepsy surgery: an update. Neurosurg Rev (2016) 0.75
Emerging drugs for partial-onset epilepsy: a review of brivaracetam. Ther Clin Risk Manag (2016) 0.75
ILAE official report: a practical clinical definition of epilepsy. Epilepsia (2014) 7.12
Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology (2006) 4.72
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol (2010) 2.96
Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol (2012) 2.79
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol (2007) 2.44
The King-Devick test and sports-related concussion: study of a rapid visual screening tool in a collegiate cohort. J Neurol Sci (2011) 2.43
Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol (2007) 2.43
In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology (2013) 2.43
Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol (2013) 2.22
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology (2013) 2.06
Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol (2002) 2.05
Laser pointer visual field screening. J Neuroophthalmol (2003) 2.03
Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol (2009) 1.85
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial. Neurology (2015) 1.84
Common data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE project. Epilepsia (2011) 1.83
Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol (2011) 1.80
Functional MRI predicts post-surgical memory following temporal lobectomy. Brain (2004) 1.71
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia (2013) 1.69
Validation and test characteristics of a 10-item neuro-ophthalmic supplement to the NEI-VFQ-25. Am J Ophthalmol (2006) 1.66
Electrical stimulation of the anterior nucleus of the thalamus for the treatment of intractable epilepsy. Epilepsia (2004) 1.58
Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics (2011) 1.57
Sudden unexpected death in epilepsy: assessing the public health burden. Epilepsia (2014) 1.56
Near infrared muscle spectroscopy in patients with Friedreich's ataxia. Muscle Nerve (2002) 1.53
Is refractory epilepsy preventable? Epilepsia (2002) 1.52
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS. Neurology (2012) 1.51
Functional visual loss in idiopathic intracranial hypertension. Ophthalmology (2009) 1.51
Optic nerve head component responses of the multifocal electroretinogram in MS. Neurology (2013) 1.46
Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology. Brain (2010) 1.45
Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS (2011) 1.45
The role of unilateral temporal artery biopsy. Ophthalmology (2003) 1.44
Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. Arch Neurol (2009) 1.43
Optic nerve biopsy in the management of progressive optic neuropathy. J Neuroophthalmol (2012) 1.37
In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques. J Neurol (2012) 1.36
Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. Ophthalmology (2013) 1.36
Sports-related concussion: Anonymous survey of a collegiate cohort. Neurol Clin Pract (2013) 1.35
Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler (2010) 1.29
Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord (2010) 1.29
Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol (2012) 1.27
The Neurological Complications of Nutritional Deficiency following Bariatric Surgery. J Obes (2012) 1.27
Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol (2011) 1.25
Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol (2008) 1.25
Retinal imaging by laser polarimetry and optical coherence tomography evidence of axonal degeneration in multiple sclerosis. Arch Neurol (2008) 1.20
One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol (2011) 1.17
Saccades and memory: baseline associations of the King-Devick and SCAT2 SAC tests in professional ice hockey players. J Neurol Sci (2013) 1.14
Predictors of future publication record and academic rank in a cohort of neurology residents. Neurology (2006) 1.13
Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol (2014) 1.12
Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (2009) 1.11
Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol (2010) 1.10
The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials. PLoS One (2011) 1.09
A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav (2003) 1.09
Retinal ganglion cell layer volumetric assessment by spectral-domain optical coherence tomography in multiple sclerosis: application of a high-precision manual estimation technique. J Neuroophthalmol (2011) 1.07
Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav (2012) 1.04
Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia (2012) 1.04
Acute ocular motor mononeuropathies: prospective study of the roles of neuroimaging and clinical assessment. J Neurol Sci (2004) 1.04
Multiple sclerosis: can retinal imaging accurately detect optic neuritis? Nat Rev Neurol (2010) 1.01
Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology (2009) 0.99
Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol (2005) 0.99
Hippocampal volumetry and functional MRI of memory in temporal lobe epilepsy. Epilepsy Behav (2009) 0.98
Neurosyphilis and status epilepticus: case report and literature review. Epilepsy Res (2004) 0.95
Self-reported visual dysfunction in multiple sclerosis: new data from the VFQ-25 and development of an MS-specific vision questionnaire. Am J Ophthalmol (2002) 0.95
Antioxidant use in Friedreich ataxia. J Neurol Sci (2007) 0.95
Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord (2005) 0.95
Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials. Epilepsia (2002) 0.94
Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf (2004) 0.94
Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: an exploratory, placebo-controlled study. Epilepsy Res (2007) 0.93
Clinical trials for therapeutic assessment of antiepileptic drugs in the 21st century: obstacles and solutions. Lancet Neurol (2012) 0.92
Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord (2003) 0.91
Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. J Neuroophthalmol (2012) 0.90
Contrast letter acuity as a measure of visual dysfunction in patients with Friedreich ataxia. J Neuroophthalmol (2002) 0.90
Adding Vision to Concussion Testing: A Prospective Study of Sideline Testing in Youth and Collegiate Athletes. J Neuroophthalmol (2015) 0.89
Health related quality of life measures in Friedreich Ataxia. J Neurol Sci (2008) 0.87
Evolution and prospects for intracranial pharmacotherapy for refractory epilepsies: the subdural hybrid neuroprosthesis. Epilepsy Res Treat (2010) 0.87
Cross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population. J Neurol Sci (2011) 0.86
Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther (2011) 0.85
Suicidal ideation and behavior screening in intractable focal epilepsy eligible for drug trials. Epilepsia (2013) 0.85
Issues for new antiepilepsy drug development. Curr Opin Neurol (2013) 0.84
Retinal damage and vision loss in African American multiple sclerosis patients. Ann Neurol (2015) 0.84
Analysis of the visual system in Friedreich ataxia. J Neurol (2013) 0.83
Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol (2010) 0.83
Is the epilepsy responsive or resistant? Only time will tell. Ann Neurol (2009) 0.83
Baseline retinal nerve fiber layer thickness and macular volume quantified by OCT in the North American phase 3 fingolimod trial for relapsing-remitting multiple sclerosis. J Neuroophthalmol (2013) 0.82
Pituitary apoplexy causing optic neuropathy and horner syndrome without ophthalmoplegia. J Neuroophthalmol (2003) 0.82
Catamenial epilepsy: the elusive condition. Epilepsy Curr (2005) 0.82
Tiagabine in clinical practice: effects on seizure control and behavior. Epilepsy Behav (2013) 0.80
The latest on optical coherence tomography. J Neuroophthalmol (2014) 0.80
Febrile seizures: possible outcomes. Neurology (2012) 0.80
VNS Therapy versus the latest antiepileptic drug. Epileptic Disord (2005) 0.79
Sports-related concussion testing. Curr Neurol Neurosci Rep (2012) 0.79
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. Mult Scler (2013) 0.79
Asymmetric bilateral demyelinating optic neuropathy from tacrolimus toxicity. J Neurol Sci (2010) 0.79
Comparison of the antiepileptic properties of transmeningeally delivered muscimol, lidocaine, midazolam, pentobarbital and GABA, in rats. Neurosci Lett (2009) 0.78
Active control trials for epilepsy: avoiding bias in head-to-head trials. Neurology (2006) 0.78
Transmeningeal muscimol can prevent focal EEG seizures in the rat neocortex without stopping multineuronal activity in the treated area. Brain Res (2011) 0.78